{"id":7956,"date":"2024-02-07T11:06:37","date_gmt":"2024-02-07T10:06:37","guid":{"rendered":"https:\/\/blog.caixaresearch.org\/?p=7956"},"modified":"2024-02-07T14:29:50","modified_gmt":"2024-02-07T13:29:50","slug":"un-sistema-innovador-de-vacunacio-contra-el-cancer","status":"publish","type":"post","link":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/","title":{"rendered":"Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/qU6OXEsoD8c?si=1Tw_JMaouJUQv8e8\" width=\"400\" height=\"225\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">\ufeff<\/span><\/iframe><\/p>\n<p>En aquesta edici\u00f3 de\u00a0<em>News From the Lab<\/em> us presentem els resultats d&#8217;un nou estudi publicat a la revista <a href=\"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04843-8?utm_source=rct_congratemailt&amp;utm_medium=email&amp;utm_campaign=oa_20240103&amp;utm_content=10.1186\/s12967-023-04843-8\" target=\"_blank\" rel=\"noopener\">Journal of Translational Medicine<\/a>, realitzat per <a href=\"https:\/\/www.irsicaixa.es\/es\" target=\"_blank\" rel=\"noopener\">l&#8217;Institut de Recerca del Sida IrsiCaixa<\/a> i el Barcelona Supercomputing Center &#8211; Centro Nacional de Supercomputaci\u00f3n (BSC-CNS). <strong>Els investigadors han desenvolupat un sistema innovador de vacunaci\u00f3 que, en estudis precl\u00ednics, ha demostrat reduir la progressi\u00f3 del melanoma<\/strong>, el c\u00e0ncer de pell m\u00e9s agressiu responsable del 80% de les morts per aquest tipus de c\u00e0ncer.<\/p>\n<p>El melanoma \u00e9s un tumor que pot manifestar-se inicialment amb lesions molt petites i estendre&#8217;s per l&#8217;organisme fins a originar met\u00e0stasi, les quals solen ser la principal causa de mortalitat.<\/p>\n<p><em><strong>Algorisme inform\u00e0tic optimitzat<\/strong><\/em><\/p>\n<p>Una caracter\u00edstica distintiva de les c\u00e8l\u00b7lules canceroses \u00e9s la pres\u00e8ncia de neoant\u00edgens, unes prote\u00efnes absents en les c\u00e8l\u00b7lules sanes. Des de fa temps, la comunitat cient\u00edfica els ha convertit en<strong> dianes terap\u00e8utiques del c\u00e0ncer<\/strong>, ja que poden <strong>estimular el sistema immunitari i ajudar el cos a combatre les c\u00e8l\u00b7lules tumorals<\/strong>. No obstant aix\u00f2, no tots els neoant\u00edgens s\u00f3n igual d&#8217;immunog\u00e8nics, \u00e9s a dir, no tots tenen la mateixa capacitat d&#8217;activar el sistema immunitari.<\/p>\n<p><strong>Escollir els millors candidats a l&#8217;hora de desenvolupar ter\u00e0pies no \u00e9s tasca f\u00e0cil<\/strong>, per\u00f2 aquest estudi ha aconseguit crear un <strong>algorisme inform\u00e0tic per identificar neoant\u00edgens altament immunog\u00e8nics amb la finalitat de dissenyar vacunes<\/strong>. \u00abQuan el cos detecta una mol\u00e8cula aliena, les nostres defenses activen totes les alarmes d&#8217;emerg\u00e8ncia. <strong>L&#8217;objectiu del nostre estudi \u00e9s trobar el neoant\u00edgen que desencadeni una resposta immunit\u00e0ria m\u00e9s potent\u00bb<\/strong>, detalla<strong> <a href=\"https:\/\/www.irsicaixa.es\/es\/carmen-aguilar-gurrieri\" target=\"_blank\" rel=\"noopener\">Carmen Aguilar<\/a><\/strong>, investigadora s\u00e8nior d&#8217;IrsiCaixa i coautora de l&#8217;estudi.<\/p>\n<div id=\"attachment_7962\" style=\"width: 410px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-7962\" class=\"wp-image-7962\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg\" alt=\"\" width=\"400\" height=\"225\" srcset=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg 2560w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-300x169.jpg 300w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-1024x576.jpg 1024w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-768x432.jpg 768w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-1536x864.jpg 1536w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-2048x1152.jpg 2048w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><p id=\"caption-attachment-7962\" class=\"wp-caption-text\"><em>Carmen Aguilar, col\u00edder de l&#8217;estudi i investigadora s\u00e8nior de l&#8217;IrsiCaixa<\/em><\/p><\/div>\n<p><em><strong>Vacunes basades en VLPS<\/strong><\/em><\/p>\n<p>Un cop identificats els neoant\u00edgens amb aquest nou algorisme, \u00e9s crucial trobar la manera d&#8217;administrar-los als pacients. <strong>IrsiCaixa compta amb una plataforma de Part\u00edcules Similars a Virus<\/strong> (VLPs, de les seves sigles en angl\u00e8s Virus Like Particles), una tecnologia patentada per la instituci\u00f3 que originalment es va desenvolupar per combatre el VIH i que ara s&#8217;ha revelat com una eina inestimable en la lluita contra el c\u00e0ncer.<\/p>\n<p>Els investigadors han administrat les vacunes dissenyades amb aquesta nova tecnologia a models precl\u00ednics de <strong>melanoma i han observat una reducci\u00f3 del creixement tumoral i una millora en la superviv\u00e8ncia<\/strong>. \u00abL&#8217;avantatge d&#8217;utilitzar VLPs en comparaci\u00f3 amb altres tecnologies \u00e9s que en cada part\u00edcula podem afegir al voltant de 15 neoant\u00edgens diferents. Aix\u00f2 afavoreix que l&#8217;organisme pugui produir una resposta immunit\u00e0ria ampla contra el tumor\u00bb, comenta <a href=\"https:\/\/www.irsicaixa.es\/es\/julia-blanco-arbues\" target=\"_blank\" rel=\"noopener\">Juli\u00e0 Blanco<\/a>, co-l\u00edder de l&#8217;estudi i investigador principal d&#8217;IrsiCaixa.<\/p>\n<p>\u00abAquestes part\u00edcules similars a virus es poden modificar &#8216;a la carta&#8217; i ens permeten introduir diferents combinacions de neoant\u00edgens, aconseguint arribar a la personalitzaci\u00f3 d&#8217;aquestes vacunes. Aquesta modificaci\u00f3 &#8216;a la carta&#8217; ens permet ampliar la diana i dirigir-nos a diferents tipus de c\u00e0ncers amb la mateixa plataforma. De fet, actualment, des d&#8217;IrsiCaixa estem treballant tamb\u00e9 amb altres tipus de c\u00e0ncers, incloent-hi el c\u00e0ncer de mama triple negatiu, de cap i coll i de p\u00e0ncrees\u00bb, exposa <a href=\"https:\/\/www.irsicaixa.es\/es\/nuria-de-la-iglesia-zaragoza\" target=\"_blank\" rel=\"noopener\">N\u00faria de la Iglesia<\/a>, investigadora principal i responsable de la l\u00ednia de recerca en c\u00e0ncer a IrsiCaixa.<\/p>\n<p>Comparades amb altres tecnologies de disseny de vacunes, les VLPs presenten diversos avantatges: <strong>s\u00f3n segures, ja que no poden replicar-se en l&#8217;organisme; indueixen una resposta immunit\u00e0ria r\u00e0pida i potent a causa de la seva similitud en mida i estructura als virus; i, a m\u00e9s dels ant\u00edgens d&#8217;inter\u00e8s, poden carregar immunomoduladors per afavorir una resposta immunit\u00e0ria m\u00e9s efectiva.<\/strong> \u00abAmb tots aquests avantatges i els resultats obtinguts fins ara, creiem que la immunoter\u00e0pia personalitzada en c\u00e0ncer podria trobar en la vacunaci\u00f3 basada en VLPs una opci\u00f3 prometedora per al futur\u00bb, conclou <a href=\"https:\/\/www.irsicaixa.es\/es\/jorge-carrillo-molina\" target=\"_blank\" rel=\"noopener\">Jorge Carrillo<\/a>, col\u00edder de l&#8217;estudi i investigador principal d&#8217;IrsiCaixa.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/qU6OXEsoD8c?si=1Tw_JMaouJUQv8e8\" width=\"400\" height=\"225\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\">\ufeff<\/iframe><\/p>\n<p>En aquesta edici\u00f3 de\u00a0<em>News From the Lab<\/em> us presentem els resultats d&#8217;un nou estudi publicat a la revista <a href=\"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04843-8?utm_source=rct_congratemailt&amp;utm_medium=email&amp;utm_campaign=oa_20240103&amp;utm_content=10.1186\/s12967-023-04843-8\" target=\"_blank\" rel=\"noopener\">Journal of Translational Medicine<\/a>, realitzat per <a href=\"https:\/\/www.irsicaixa.es\/es\" target=\"_blank\" rel=\"noopener\">l&#8217;Institut de Recerca del Sida IrsiCaixa<\/a> i el Barcelona Supercomputing Center &#8211; Centro Nacional de Supercomputaci\u00f3n (BSC-CNS). Els investigadors han desenvolupat un sistema innovador de vacunaci\u00f3 que, en estudis precl\u00ednics, ha demostrat reduir la progressi\u00f3 del melanoma, el c\u00e0ncer de pell m\u00e9s agressiu responsable del 80% de les morts per aquest tipus de c\u00e0ncer.<\/p>\n<p>El melanoma \u00e9s un tumor que pot manifestar-se inicialment amb lesions molt petites i estendre&#8217;s per l&#8217;organisme fins a originar met\u00e0stasi, les quals solen ser la principal causa de mortalitat.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[340],"tags":[],"class_list":["post-7956","post","type-post","status-publish","format-standard","hentry","category-sense-categoria"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer - Blog CaixaCi\u00e8ncia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer - Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"og:description\" content=\"\ufeff En aquesta edici\u00f3 de\u00a0News From the Lab us presentem els resultats d&#8217;un nou estudi publicat a la revista Journal of Translational Medicine, realitzat per l&#8217;Institut de Recerca del Sida IrsiCaixa i el Barcelona Supercomputing Center &#8211; Centro Nacional de Supercomputaci\u00f3n (BSC-CNS). Els investigadors han desenvolupat un sistema innovador de vacunaci\u00f3 que, en estudis precl\u00ednics, ha demostrat reduir la progressi\u00f3 del melanoma, el c\u00e0ncer de pell m\u00e9s agressiu responsable del 80% de les morts per aquest tipus de c\u00e0ncer. El melanoma \u00e9s un tumor que pot manifestar-se inicialment amb lesions molt petites i estendre&#8217;s per l&#8217;organisme fins a originar met\u00e0stasi, les quals solen ser la principal causa de mortalitat.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-07T10:06:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-07T13:29:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg\" \/>\n<meta name=\"author\" content=\"Ubikmedia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ubikmedia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/\",\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/\",\"name\":\"Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer - Blog CaixaCi\u00e8ncia\",\"isPartOf\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg\",\"datePublished\":\"2024-02-07T10:06:37+00:00\",\"dateModified\":\"2024-02-07T13:29:50+00:00\",\"author\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/#primaryimage\",\"url\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg\",\"contentUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\",\"url\":\"https:\/\/blog.caixaresearch.org\/\",\"name\":\"Blog CaixaCi\u00e8ncia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.caixaresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\",\"name\":\"Ubikmedia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"caption\":\"Ubikmedia\"},\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer - Blog CaixaCi\u00e8ncia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/","og_locale":"ca_ES","og_type":"article","og_title":"Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer - Blog CaixaCi\u00e8ncia","og_description":"\ufeff En aquesta edici\u00f3 de\u00a0News From the Lab us presentem els resultats d&#8217;un nou estudi publicat a la revista Journal of Translational Medicine, realitzat per l&#8217;Institut de Recerca del Sida IrsiCaixa i el Barcelona Supercomputing Center &#8211; Centro Nacional de Supercomputaci\u00f3n (BSC-CNS). Els investigadors han desenvolupat un sistema innovador de vacunaci\u00f3 que, en estudis precl\u00ednics, ha demostrat reduir la progressi\u00f3 del melanoma, el c\u00e0ncer de pell m\u00e9s agressiu responsable del 80% de les morts per aquest tipus de c\u00e0ncer. El melanoma \u00e9s un tumor que pot manifestar-se inicialment amb lesions molt petites i estendre&#8217;s per l&#8217;organisme fins a originar met\u00e0stasi, les quals solen ser la principal causa de mortalitat.","og_url":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/","og_site_name":"Blog CaixaCi\u00e8ncia","article_published_time":"2024-02-07T10:06:37+00:00","article_modified_time":"2024-02-07T13:29:50+00:00","og_image":[{"url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg","type":"","width":"","height":""}],"author":"Ubikmedia","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Ubikmedia","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/","url":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/","name":"Un sistema innovador de vacunaci\u00f3 contra el c\u00e0ncer - Blog CaixaCi\u00e8ncia","isPartOf":{"@id":"https:\/\/blog.caixaresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/#primaryimage"},"image":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg","datePublished":"2024-02-07T10:06:37+00:00","dateModified":"2024-02-07T13:29:50+00:00","author":{"@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/ca\/un-sistema-innovador-de-vacunacio-contra-el-cancer\/#primaryimage","url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg","contentUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2024\/02\/CarmenAguilar_Blog-scaled.jpg"},{"@type":"WebSite","@id":"https:\/\/blog.caixaresearch.org\/#website","url":"https:\/\/blog.caixaresearch.org\/","name":"Blog CaixaCi\u00e8ncia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.caixaresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca","name":"Ubikmedia","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","caption":"Ubikmedia"},"url":"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/7956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/comments?post=7956"}],"version-history":[{"count":6,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/7956\/revisions"}],"predecessor-version":[{"id":7970,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/7956\/revisions\/7970"}],"wp:attachment":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media?parent=7956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/categories?post=7956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/tags?post=7956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}